Meet Senzime at Euroanesthesia 2017

Uppsala, May 24, 2017.  Senzime AB (publ) will be participating at Euroanaesthesia 2017 in Geneva, Switzerland June 3-5, 2017. 

Euroanaesthesia is Europe’s largest annual event showcasing the latest and the most relevant knowledge with medical experts active in the field of anaesthesia, perioperative medicine, intensive care, emergency medicine and pain treatment.

This international event gathers thousands of delegates and exhibitors from over 80 countries. Upwards of 6000 delegates are expected from all over the world.

Senzime is exhibiting at the meeting, please visit us at our booth #17

For further information, please contact:

Lena Söderström, CEO at Senzime AB

Tel: +46 708-16 39 12, email: lena.soderstrom@senzime.com

TO THE EDITORS  

About Senzime  

Senzime develops unique patient-oriented monitoring systems that make it possible to assess patients' biochemical and physiological processes before, during and after surgery. The portfolio of technologies includes bedside systems that enable automated and continuous monitoring of life-critical substances such as glucose and lactate in both blood and tissues, as well as systems to monitor patients’ neuromuscular function perioperatively and in the intensive care medicine setting. The solutions are designed to ensure maximum patient benefit, reduce complications associated with surgery and anesthesia, and decrease health care costs. Senzime operates in growing markets that in Europe and the United States are valued in excess of SEK 10 billion. The company's shares are listed on Nasdaq First North (ticker SEZI). FNCA is Certified Adviser for Senzime. www.senzime.com